| Literature DB >> 36230655 |
Abir Troudi1, Fatima Tensaouti1,2, Eloise Baudou1,3, Patrice Péran1, Anne Laprie1,2.
Abstract
Arterial spin labeling (ASL) is a magnetic resonance imaging (MRI) technique for measuring cerebral blood flow (CBF). This noninvasive technique has added a new dimension to the study of several pediatric tumors before, during, and after treatment, be it surgery, radiotherapy, or chemotherapy. However, ASL has three drawbacks, namely, a low signal-to-noise-ratio, a minimum acquisition time of 3 min, and limited spatial summarize current resolution. This technique requires quality control before ASL-CBF maps can be extracted and before any clinical investigations can be conducted. In this review, we describe ASL perfusion principles and techniques, summarize the most recent advances in CBF quantification, report technical advances in ASL (resting-state fMRI ASL, BOLD fMRI coupled with ASL), set out guidelines for ASL quality control, and describe studies related to ASL-CBF perfusion and qualitative and semi-quantitative ASL weighted-map quantification, in healthy children and those with pediatric brain tumors.Entities:
Keywords: arterial spin labeling; cerebral blood flow; pediatric tumor; perfusion MRI; quality control
Year: 2022 PMID: 36230655 PMCID: PMC9564035 DOI: 10.3390/cancers14194734
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1General principle of ASL.
Figure 2Schematic representation of the CASL sequence. EPI: echo planar imaging module; TE: echo time; PLD: post labeling delay; TR: repetition time; Gz: gradient.
Figure 3Schematic representation of the PASL sequence. EPI: echo planar imaging module; TE: echo time; TI: inversion time; TR: repetition time; Gz: gradient.
Figure 4Schematic representation of the pCASL sequence. EPI: echo planar imaging module; TE: echo time; PLD: post-labeling delay; TR: repetition time; Gz: gradient.
Figure 5Schematic representation of the VSASL sequence. PLD: post-labeling delay; TI: inversion time; TR: repetition time.
Illustration of the different ASL and rs-BOLD fMRI acquisition parameters described in [46].
| Acquisition Parameters | ASL Acquisition | Rs-BOLD fMRI |
|---|---|---|
| Acquisition type | CASL | echo-planar gradient |
| PLD | 1000 ms | - |
| Labeling time | 2000 ms | - |
| In-plane resolution | 220 × 220 mm2 | 220 × 220 mm2 |
| TE | 17 ms | 30 ms |
| TR | 3800 ms | 3000 ms |
| Flip angle | 90° | 90° |
| Slice thickness | 7 mm | 3 mm |
| Inter-slice gap | 2.35 mm | - |
| Matrix | 64 × 64 × 12 | 64 × 64 |
| Image number | 50 labeled/control image pairs | 220 images |
Common artifacts and their definitions.
| Common Artifacts | Definitions |
|---|---|
| Motion artifacts | Appear as rings or curved lines and can cause artificially high or low CBF values. |
| Signal loss | Results from susceptibility effects with EPI-based playback sequences. These typically occur at air-tissue interfaces, such as near the frontal sinuses or the mastoid bone. |
| Distortions | |
| Bright spots (or macrovascular artifacts) | Are random clusters of very high perfusion voxels caused by the residual vascular signal. |
| Hyper/Hypo-perfusion | Is sometimes visible on perfusion maps, without being either a pathological or acquisition artifact. This constitutes a physiological change in perfusion. |
| Labeling failure | Failure to label incoming blood due to local susceptibility artifacts results in an apparent lack of perfusion throughout the affected vascular territory. |
Absolute CBF values (mL/100 g/min) for each age group for the whole brain, gray matter (GM) and white matter (WM) [16].
| Imaging Technique: 3D Pulsed ASL on 1.5T MAGNETOM Aera | |||
|---|---|---|---|
| Age | Whole Brain CBF | CBF in GM | CBF in WM |
| 6–11 months | 53.3 ± 7.8 | 58.6 ± 8.3 | 29.2 ± 5.1 |
| 12–23 months | 61.7 ± 3.2 | 68.2 ± 3.5 | 39.3 ± 2.5 |
| 2–3 years | 68.5 ± 4.4 | 76.5 ± 4.9 | 40.2 ± 4.5 |
| 4–5 years | 56.6 ± 3.8 | 64.9 ± 4.3 | 26.0 ± 2.1 |
| 6–7 years | 62.4 ± 3.0 | 71.4 ± 3.1 | 30.5 ± 2.3 |
| 8–9 years | 54.9 ± 2.7 | 63.9 ± 3.1 | 25.8 ± 1.8 |
| 10–11 years | 53.4 ± 5.2 | 62.4 ± 6.1 | 23.9 ± 2.6 |
| 12–13 years | 43.3 ± 2.6 | 51.0 ± 3.0 | 21.7 ± 2.0 |
| 14–15 years | 50.1 ± 2.0 | 59.3 ± 2.5 | 24.8 ± 1.2 |
Absolute CBF values (mL/100 g/min) for each tumor ROI [19].
| Imaging Technique: Axial 3D Pseudo Continuous ASL with 16-Channel Head Coil in a 1.5 T MRI Machine | |
|---|---|
| Tumor Type | CBF |
| Medulloblastoma | 16.02 |
| Pilocytic astrocytoma | 9.28 |
Absolute CBF values (mL/100/min) according to age, brain structure, and tumor [57].
| Imaging Technique: 3D Pseudo Continuous ASL MR Imaging on a GE Signa HDxt 1.5 T System with a 12-Channel Head-Neck-Spine Coil | |||
|---|---|---|---|
| Age in Years | Brain Structure | Tumor Type | CBF without Treatment |
| 2.3–9.5 | Posterior fossa | Pilocytic astrocytoma | 32 (25–40) |
| 4.6–10.5 | Medulloblastoma | 59 (48–87) | |
| 1.2–2.6 | Grade 3 ependymoma | 82 (47–142) | |
| 2.7–5.6 | Thalamus | Pilocytic astrocytoma | 36 (30–40) |
| 8.9–14.2 | Grade 3 astrocytoma | 73 (64–241) | |
| 6.6–7.4 | Glioblastoma | 94 (90–97) | |
| 4.9–12.7 | Hemispheres | Glioblastoma | 117 (100–130) |
Absolute CBF values (mL/100 g/min) within both tumor and healthy tissue regions of interest [17].
| Imaging Technique: Spin Tagging with Alternating RF Labeling Scheme (STAR) with a Look–Locker Readout on a 3T Philips Achieva | ||
|---|---|---|
| Tumor Type | CBF | |
| CBF in control regions | - | 75 |
| CBF in tumor regions | Low-grade glioma | 87 |
| Medulloblastoma | 111 | |
p values for median CBF in ependymoma survivors versus healthy children of the same age [20].
| Imaging Technique: 3D Pseudo Continuous Labeling on a 3 T MRI Scanner | |
|---|---|
| Brain Structure | |
| White matter | 0.749 |
| Cerebral cortex | 0.742 |
| Thalamus | 0.650 |
| Caudate |
|
| Putamen | 0.124 |
| Globus pallidus |
|
Bold: The statistically significant differences in regional CBF in these brain structures compared with healthy controls.
Absolute CBF values (mL/100 g/min) [18].
| Imaging Technique: Pseudo-Continuous ASL Sequence on a Philips Achieva 3T TX System (Best, The Netherlands) Using a 32-Channel Head Coil | |||
|---|---|---|---|
| Age (Years) | Brain Structure | Tumor Type | Absolute CBF Value |
| 11.3 | Thalamus | Pilocytic astrocytoma | 79.49 |
| 4.8 | Optic chiasm | Pilocytic astrocytoma | 86.12 |
| 3.9 | Optic chiasm | Pilocytic astrocytoma | 56.03 |
| 2.8 | Optic chiasm | Pilocytic astrocytoma | 52.50 (chemotherapy only) |
| 5.6 | Optic pathway | Pilocytic astrocytoma | 48.21 (chemotherapy only) |
| 2.1 | Left hemisphere | Glioblastoma | 10.94 |
| 5.3 | Optic pathway | Low grade glioma | 82.62 (chemotherapy only) |
Absolute CBF values (mL/100 g/min) in patients treated for medulloblastomas and neurologically normal children [11].
| Imaging Technique: 3D Pseudo-Continuous Labeling on a 3T MRI Scanner | ||
|---|---|---|
| Brain Structure | Absolute CBF Values in Healthy Controls | Absolute CBF Values in Patients with Medulloblastoma |
| White matter | 45.6–49.2 | 37.9–44.4 |
| Cerebral cortex | 64.2–69.7 | 47.8–57.9 |
| Thalamus | 53.4–58.2 | 38.6–47.3 |
| Caudate | 53.1–56.8 | 43.8–50.6 |
| Putamen | 54.9–58.6 | 44.6–51.4 |
| Globus pallidus | 42.3–45.9 | 32.9–39.4 |
| Hippocampus | 52.2–56.5 | 41.1–49 |
| Amygdala | 49–53.2 | 37.4–44.9 |
| Nucleus accumbens | 56.5–60.6 | 49.1–56.7 |
Relative tumor blood flow (rTBF) values in different pediatric tumors, age of patients, and tumor location [6].
| Tumor Type | Mean Age (Years) | Tumor Location | rTBF |
|---|---|---|---|
| Glioblastoma | 13 ± 8.5 | Cerebrum | 3.70 ± 1.89 |
| Anaplastic astrocytoma | 11 | Cerebrum | 3.60 |
| Medulloblastoma | 6.1 ± 3.7 | Posterior fossa | 2.87 ± 1.74 |
| Pilocytic astrocytoma | 9.4 ± 6.1 | Cerebrum, Cerebellum, Brainstem | 1.05 ± 0.19 |
| Ependymoma | 3 | Posterior fossa | 1.82 |
rTBF values for different pediatric tumors according to age [64].
| Histopathology | Age (Years) | Sex | rTBF |
|---|---|---|---|
| Pilocytic astrocytoma | 3 | Male | 0.54 |
| Pilocytic astrocytoma | 3 | Female | 0.29 |
| Pilocytic astrocytoma | 6 | Male | 0.36 |
| Pilocytic astrocytoma | 11 | Female | 0.53 |
| Glioblastomas | 9 | Female | 0.78 |
| Anaplastic ependymoma | 2 | Female | 2.00 |
| Anaplastic ependymoma | 3 | Male | 1.44 |
| Anaplastic ependymoma | 6 | Female | 1.98 |
| Medulloblastoma | 9 | Male | 3.59 |
| Medulloblastoma | 11 | Male | 0.82 |